浙江万丰化工股份有限公司 特定股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603172 证券简称：万丰股份 公告编号：2025-022 上述减持主体无一致行动人。 二、减持计划的实施结果 重要内容提示： 特定股东的基本情况 本次减持计划实施前，舟山瑞好股权投资有限公司（以下简称"舟山瑞好"） 持有浙江万丰化工股份有限公司（以下简称"公司"）无限售条件流通股 5,000,000 股，占公司总股本的 3.75%，属于公司特定股东。上述股份来源 为公司首次公开发行股票并上市前已有的股份。 减持计划的实施结果情况 2025 年 7 月 25 日，公司披露《浙江万丰化工股份有限公司关于特定股东 减持股份计划公告》（公告编号：2025-021）：舟山瑞好计划以大宗交易方 式减持公司股份不超过 2,667,600 股，即不超过公司总股本的 2.00%；自 减持计划公告之日起十五个交易日后的 90 天内（2025 年 8 月 15 日至 2025 年 11 月 12 日）进行。截至本公告日，舟山瑞 ...

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

重要内容提示： 浙江万丰化工股份有限公司 关于特定股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603172 证券简称：万丰股份 公告编号：2025-21 | 股东名称 | 舟山瑞好 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股东 | | | | 持股数量 | 5,000,000股 | | | | 持股比例 | 3.75% | | | | 当前持股股份来源 | IPO 前取得：5,000,000股 | | | 一、减持主体的基本情况 1 股东持股的基本情况：截至本公告披露日，浙江万丰化工股份有限公 司（以下简称"公司"）股东舟山瑞好股权投资有限公司（曾用名"宁 波瑞好投资有限公司"，以下简称"舟山瑞好"）持有公司无限售条件 流通股 5,000,000 股（占 ...

万丰股份（603172）公告，公司股东舟山瑞好因自身资金需求，计划通过大宗交易方式减持公司股份不 超过266.76万股，即不超过公司当前总股本的2%。舟山瑞好目前持有公司500万股，占总股本的 3.75%。此次减持计划将于公告发布十五个交易日后的90天内实施，预计时间范围为2025年8月15日至 2025年11月12日。公司将督促股东合规减持，并及时履行信息披露义务。该减持计划不会对公司治理结 构及未来持续经营产生重大影响。 ...

[Core Summary of Performance Forecast](index=1&type=section&id=Important%20Content%20Reminder) The company anticipates a net profit attributable to shareholders of **22 to 26 million yuan** for H1 2025, a **67.72% to 98.21%** increase, with non-recurring net profit expected at **21.3 to 25.3 million yuan**, growing **67.34% to 98.76%**, driven by enhanced profitability | Indicator | 2025 H1 Estimate (Million Yuan) | Increase from Prior Year (Million Yuan) | Year-over-Year Growth | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 22.00 - 26.00 | 8.8828 - 12.8828 | 67.72% - 98.21% | | **Non-recurring Net Profit Attributable to Shareholders** | 21.30 - 25.30 | 8.5711 - 12.5711 | 67.34% - 98.76% | [Details of Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) This report details the performance forecast for January 1 to June 30, 2025, projecting significant growth in both net profit attributable to shareholders and non-recurring net profit, based on preliminary unaudited estimates - The performance forecast covers the period from January 1 to June 30, 2025[3](index=3&type=chunk) | Indicator | 2025 H1 Estimate (Million Yuan) | Year-over-Year Growth | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 22.00 - 26.00 | 67.72% - 98.21% | | **Non-recurring Net Profit Attributable to Shareholders** | 21.30 - 25.30 | 67.34% - 98.76% | - The company explicitly states that this performance forecast is a preliminary estimate and has not been audited by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance Review](index=2&type=section&id=II.%20Operating%20Performance%20and%20Financial%20Status%20in%20Prior%20Period) The report reviews H1 2024 financial data as a comparative baseline, with net profit attributable to shareholders at **13.1172 million yuan**, non-recurring net profit at **12.7289 million yuan**, and EPS at **0.10 yuan**, providing a low base for current period growth | Indicator (2024 H1) | Amount/Value | | :--- | :--- | | Total Profit | 15.7719 Million Yuan | | Net Profit Attributable to Shareholders | 13.1172 Million Yuan | | Non-recurring Net Profit Attributable to Shareholders | 12.7289 Million Yuan | | Earnings Per Share | 0.10 Yuan/Share | [Analysis of Performance Increase Reasons](index=2&type=section&id=III.%20Primary%20Reasons%20for%20Current%20Period%20Performance%20Increase) Significant H1 2025 performance growth is primarily attributed to successful international market expansion, effective cost reduction and efficiency improvement measures, and a lower comparative base from the prior year, collectively boosting sales and gross margin - Key drivers for performance growth include: - **International Market Expansion**: Successful overseas market development, product alignment with customer needs, and tariff policy impacts led to significant growth in international sales[6](index=6&type=chunk) - **Cost Control**: The company continuously implemented cost reduction and efficiency improvement measures, enhancing operational efficiency and driving overall gross margin growth[6](index=6&type=chunk) - **Low Base Effect**: A smaller comparative base from the prior year amplified the current period's performance increase[6](index=6&type=chunk) [Risk Warning and Other Notes](index=2&type=section&id=IV.%20Risk%20Warning) The company warns that this performance forecast is a preliminary, unaudited financial estimate, which may differ from the final semi-annual report, and while no major uncertainties affecting accuracy are currently identified, investors are advised to consider investment risks - This performance forecast is based on preliminary, unaudited data, and the final accurate financial figures will be subject to the company's officially disclosed 2025 semi-annual report[7](index=7&type=chunk)[8](index=8&type=chunk) - The company states that as of the announcement date, there are no significant uncertainties affecting the accuracy of this performance forecast[7](index=7&type=chunk)

Summary of Key Points Core Viewpoint - Ningbo Yixian Enterprise Management Consulting Co., Ltd. has completed its share reduction plan for Zhejiang Wanfeng Chemical Co., Ltd., reducing its holdings by 2,332,400 shares, which is 1.75% of the total share capital [1][2]. Group 1: Shareholder Information - Ningbo Yixian held 2,332,400 shares before the reduction, representing 1.75% of the total share capital, with shares acquired prior to the company's IPO [1][2]. - The shareholder does not have any concerted actions with other parties [2]. Group 2: Reduction Plan Implementation - The reduction plan was announced on May 20, 2025, and the shares were reduced through block trading from June 11, 2025, to September 8, 2025 [2]. - The total amount from the share reduction was approximately 31,930,556 yuan, with a share price range of 13.69 yuan per share [2]. - The reduction plan was fully executed, and the actual reduction matched the previously disclosed plan [2].

证券代码：603172 证券简称：万丰股份 公告编号：2025-019 浙江万丰化工股份有限公司 特定股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 特定股东的基本情况 本次减持计划实施前，宁波怡贤企业管理咨询有限公司（以下简称"宁波 怡贤"）持有浙江万丰化工股份有限公司（以下简称"公司"）无限售条件 流通股 2,332,400 股，占公司总股本的 1.75%，属于公司特定股东。上述 股份来源为公司首次公开发行股票并上市前已有的股份。 减持计划的实施结果情况 | 股东名称 | 宁波怡贤 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股东 | | | 一、减持主体减持前基本情况 2025 年 5 月 20 日，公司披露《浙江万丰化工股份有限公司关于特定股东 减 ...

Core Points - Wan Feng Co., Ltd. (万丰股份) reported a closing price of 15.21 yuan as of June 13, 2025, down 1.74% from the previous week [1] - The company's total market capitalization is 2.029 billion yuan, ranking 159th out of 169 in the chemical products sector and 4912th out of 5150 in the A-share market [1] Shareholder Changes - As of June 10, 2025, the number of shareholders increased to 9,854, an increase of 1,194 shareholders or 13.79% compared to May 30 [1][3] - The average number of shares held per shareholder decreased from 15,400 shares to 13,500 shares, with an average holding value of 213,900 yuan [1] Company Announcements - Wan Feng Co., Ltd. announced a cash dividend of 0.09 yuan per share (before tax), with the record date set for June 13, 2025, and the payment date on June 16, 2025 [1][3] - The total cash dividend distribution amounts to 12,004,200 yuan based on the company's total share capital of 133,380,000 shares [1] - Different tax treatments apply for various categories of shareholders, with a 10% withholding tax for certain shareholders and exemptions for long-term holders [1]

Group 1 - The A-share dye sector has experienced a significant rally, with companies like Baolidi hitting the daily limit of 20% increase [1] - Jihua Group previously reached its limit, indicating strong market interest and performance in the sector [1] - Other companies such as Wanfeng Co., Jinjiji Co., Qicai Chemical, Annuoqi, and Runtu Co. also saw increases, reflecting a broader trend in the dye industry [1]

Core Points - Zhejiang Wanfeng Chemical Co., Ltd. announced a cash dividend of 0.09 CNY per share (before tax) for its A shares, totaling 12,004,200 CNY based on a total share capital of 133,380,000 shares [1][2][3] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 23, 2025 [1] - Key dates for the dividend distribution include the record date on June 13, 2025, and the ex-dividend date on June 16, 2025 [1][2] Dividend Distribution Details - The company will not issue bonus shares or increase share capital as part of this distribution [2] - For individual shareholders holding unrestricted circulating shares, dividends are subject to differentiated personal income tax policies based on holding periods [3][4] - The actual cash dividend after tax for shareholders holding shares for less than one month is 0.081 CNY per share, while those holding for more than one year will not incur personal income tax [3][4] Taxation Information - Individual shareholders with a holding period exceeding one year will not be taxed on dividend income, while those with a holding period of one year or less will be taxed at a rate of 20% [3] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied to their dividends [4] - Other institutional investors are responsible for self-reporting and paying taxes on their dividend income [4]